Literature DB >> 31594208

Prognostic value of the combined expression of tumor-associated trypsin inhibitor (TATI) and p53 in patients with bladder cancer undergoing radical cystectomy.

Anwei Liu1,1, Yongping Xue1,1, Fei Liu1,1, Haoyuan Tan2,1, Qiao Xiong1, Shuxiong Zeng1, Zhensheng Zhang1, Xu Gao1, Yinghao Sun1, Chuanliang Xu1.   

Abstract

BACKGROUND: Urothelial carcinoma of the bladder is a heterogeneous disease for which reliable prognostic molecular biomarkers have not been established.
OBJECTIVE: To investigate the prognostic value of tumor-associated trypsin inhibitor (TATI) expression combined with p53 expression in bladder cancer patients who have undergone radical cystectomy.
METHODS: Tissue microarrays from 110 patients were analyzed immunohistochemically for TATI and p53 protein expression. Complete clinical-pathological information and follow-up data were collected. Univariable Kaplan-Meier analysis and log-rank test were performed to assess the association between TATI and p53 expression patterns with clinical outcomes. Cox's proportional hazard analysis was performed to identify potential independent risk factors for predicting disease progression and evaluate the prognostic value of combining the expression of TATI and p53 on progression-free survival (PFS) and overall survival (OS).
RESULTS: TATI expression was positively correlated with favorable differentiation of bladder cancer, and lower tumor stage. p53 expression was positively related to tumor stage, tumor grade, and lymph-node invasion. Univariate Kaplan-Meier analysis revealed significant differences between TATI-positive vs. TATI-negative and p53-positive vs. p53-negative patients, regarding PFS. Multivariate analysis showed that both TATI and p53 expression were independent factors for predicting disease progression.
CONCLUSION: TATI expression patterns could enhance the prognostic value of p53 overexpression on progression.

Entities:  

Keywords:  Bladder cancer; TATI; combined expression; p53; prognostic value; progression

Mesh:

Substances:

Year:  2019        PMID: 31594208     DOI: 10.3233/CBM-182143

Source DB:  PubMed          Journal:  Cancer Biomark        ISSN: 1574-0153            Impact factor:   4.388


  3 in total

1.  Noninvasive papillary urothelial carcinoma with pathological features in between low and high grades: A case report.

Authors:  Shuang Ma; Yang Han; Di Zhang; Qingchang Li; Enhua Wang; Guangping Wu; Huanyu Zhao
Journal:  Medicine (Baltimore)       Date:  2021-04-30       Impact factor: 1.817

Review 2.  Diagnostic and Prognostic Potential of Biomarkers CYFRA 21.1, ERCC1, p53, FGFR3 and TATI in Bladder Cancers.

Authors:  Milena Matuszczak; Maciej Salagierski
Journal:  Int J Mol Sci       Date:  2020-05-09       Impact factor: 5.923

Review 3.  The therapeutic and prognostic implications of molecular biomarkers in urothelial carcinoma.

Authors:  Ho Won Kang; Wun-Jae Kim; Seok Joong Yun
Journal:  Transl Cancer Res       Date:  2020-10       Impact factor: 1.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.